Name: mechanical and controlled prp injections in patients affected by androgenetic alopecia
Uploaded: 2018-01-27T14:00:00.000+00:00
Duration: 3 min 22 s
Description: Watch this Scientific Journal Video about Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia at JoVE.com

Yazarlar hiçbir ilgili kaynaklar var.

Helsinki Deklarasyonu ile çalışma Protokolü uyulması ve tüm hastalar çalışmaya katılan önce yazılı Onam sağladı.
1. sigara-harekete geçirmek A-PRP hazırlık
<ol><li>Otolog kan periferik ven bir tüp ile yerel kan toplama protokolüne göre kelebek iğne kullanarak kolu üzerinden 55 mL hasat.</li>
	<li>7 mL asit sitrat dekstroz (ACD) çözeltisi (sitrat 112 mM) kan tüpü bir antikoagülan olarak ekleyin.</li>
	<li>Santrifüj kan tüpü 10 min için 260 x g de toplanan. Not: A-PRP + Otolog trombosit-yoksul plazma (A-PPP) 23 mL ve kırmızı kan hücreleri süspansiyon (RBCs) 20 mL üretildi.</li>
	<li>A-PRP + A-PPP ve RBCs santrifüj içeren tüp çıkar ve bir lazer ışık seçici aygıt ekleyin.</li>
	<li>Ayrı A-PRP + A-PPP Mekanik emiş kitinin yerleştirildiği lazer seçici tarafından gerçekleştirilen tarafından bir steril torba. RBCs Mekanik emiş tarafından otomatik olarak kaldırılır. Not: A-PPP 14 mL el ile hasat ve teçhizat--dan steril torba tarafından kaldırıldı. A-PRP 9 mL elde edildi.</li>
</ol>2. sigara-harekete geçirmek A-PRP enjeksiyonları
<ol><li>Ön, yan, vertex ve oksipital alanları AGA tarafından etkilenen hastaların kafa derisi bölün. Dikkat: anestezi (Lokal veya sistemik) gerçekleştirme.</li>
	<li>İnterfollicular A-PRP enjeksiyonları (cm2x 0,20 mL) tarafından tıbbi enjektör gerçekleştirmek ( Tablo malzemelerigörmek) kafa derisi seçili alanları için silah.<ol>
<li>Frontal ve parietal bölgelerine lokalize saç kaybı olan hastalarda, A-PRP enjeksiyonları önden bölgesine sadece gerçekleştirmek ve parietal bölgede plasebo salin kullanın.</li>
		<li>Paryetal ve köşe bölgelerine lokalize saç kaybı olan hastalarda, A-PRP parietal bölgede enjekte ve köşe alanında plasebo salin kullanın.</li>
	</ol>
</li>
	<li>A-PRP ve plasebo enjeksiyon eşit sayıda her hasta için gerçekleştirin.</li>
	<li>5 mm 30 G iğne ve 10 mL şırınga ile donatılmış tıbbi enjektör silah kullanan bir derinlikte interfollicular A-PRP enjeksiyonları gerçekleştirin.</li>
	<li>Üç seans 30 gün arayla aralıklı gerçekleştirin.</li>
</ol>

<ol>
	<li>Rousso, D. E., Kim, S. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+review+of+medical+and+surgical+treatment+options+for+androgenetic+alopecia.">A review of medical and surgical treatment options for androgenetic alopecia.</a> JAMA Facial Plast Surg. 16, 444-450 (2014).</li><li>Schweiger, E. S., Boychenko, O., Bernstein, R. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Update+on+the+pathogenesis,+genetics+and+medical+treatment+of+patterned+hair+loss.">Update on the pathogenesis, genetics and medical treatment of patterned hair loss.</a> J Drugs Dermatol. 9, 1412-1419 (2010).</li><li>Price, V. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lack+of+efficacy+of+finasteride+in+postmenopausal+women+with+androgenetic+alopecia.">Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.</a> J Am Acad Dermatol. 43, 768-776 (2000).</li><li>Imperato-McGinley, J., Guerrero, L., Gautier, T., Peterson, R. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Steroid+5alpha-reductase+deficiency+in+man:+An+inherited+form+of+male+pseudohermaphroditism.">Steroid 5alpha-reductase deficiency in man: An inherited form of male pseudohermaphroditism.</a> Science. 186, 1213-1215 (1974).</li><li>Drake, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+effects+of+finasteride+on+scalp+skin+and+serum+androgen+levels+in+men+with+androgenetic+alopecia.">The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.</a> J Am Acad Dermatol. 41, 550-554 (1999).</li><li>Van Neste, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Finasteride+increases+anagen+hair+in+men+with+androgenetic+alopecia.">Finasteride increases anagen hair in men with androgenetic alopecia.</a> Br J Dermatol. 143, 804-810 (2000).</li><li>Kaufman, K. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Finasteride+in+the+treatment+of+men+with+androgenetic+alopecia.">Finasteride in the treatment of men with androgenetic alopecia.</a> J. Am Acad Dermatol. 39, 578-589 (1998).</li><li>Afifi, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Low-level+laser+therapy+as+a+treatment+for+androgenetic+alopecia.">Low-level laser therapy as a treatment for androgenetic alopecia.</a> Lasers Surg Med. 49, 27-39 (2017).</li><li>Uebel, C. O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+role+of+platelet+plasma+growth+factors+in+male+pattern+baldness+surgery.">The role of platelet plasma growth factors in male pattern baldness surgery.</a> Plast Reconstr Surg. 118, 1458-1466 (2006).</li><li>Cervelli, V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+effect+of+autologous+activated+platelet+rich+plasma+(AA-PRP)+injection+on+pattern+hair+loss:+Clinical+and+histomorphometric+evaluation.">The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: Clinical and histomorphometric evaluation.</a> BioMed Res Int. , 760709 (2014).</li><li>Gkini, M. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Study+of+platelet-rich+plasma+injections+in+the+treatment+of+androgenetic+alopecia+through+an+one-year+period.">Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period.</a> J Cutan Aesthet Surg. 7, 213-219 (2014).</li><li>Gentile, P., Garcovich, S., Bielli, A., Scioli, M. G., Orlandi, A., Cervelli, V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+effect+of+platelet-rich+plasma+in+hair+regrowth:+A+randomized+placebo-controlled+trial.">The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial.</a> Stem Cells Transl Med. 4, 1317-1323 (2015).</li><li>Gentile, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Evaluation+of+Not-Activated+and+Activated+PRP+in+Hair+Loss+Treatment:+Role+of+Growth+Factor+and+Cytokine+Concentrations+Obtained+by+Different+Collection+Systems.">Evaluation of Not-Activated and Activated PRP in Hair Loss Treatment: Role of Growth Factor and Cytokine Concentrations Obtained by Different Collection Systems.</a> Int J Mol Sci. 18 (2), 14 (2017).</li></ol>

Yazarlar ifşa gerek yok.

Yazarlar A-PRP mekanik ve kontrollü enjeksiyonlari azalma-cerrahın elleri tarafından gerçekleştirilen manuel enjeksiyonu ile karşılaştırıldığında yordamı sırasında ağrı ile uygun AGA tedavi seçenekleri temsil ettiğini gösterdi. Bu iletişim kuralı ile tedavi edilen hastaların saç sayısı ve toplam saç yoğunluğu büyük artışlar manuel enjeksiyonu ile tedavi edilen hastaların daha var bulunamadı.
P...

Sigara-harekete geçirmek A-PRP klinik enjeksiyon tüylerin hedefleme için çekici bir kaynak haline gelmiştir. Burada, mekanik ve kontrollü iğne kullanarak AGA A-PRP uygulamasında protokol bildirilmektedir. Şu anda, sadece sözlü selektif 5-α-redüktaz inhibitörü, topikal diaminopirimidilpiperidin-N-ossido (%2.0 ve % 5.0) ve düşük seviyeli lazer tedavisi (LLLT) onaylı MPHL1,2 mücadele için ABD Gıda ve İlaç Dairesi (FDA) tarafından .
Diaminopirimidilpiperidin-N-ossido %5 köpük de FPHL için FDA tarafından onaylanmıştır. Selektif 5-α-redüktaz inhibitörü FPHL3tedavisinde büyük ölçüde etkisiz kanıtlanmış olup, verilen ilaç anormallikler erkek fetusa dış genital içinde neden olabilir, menopoz öncesi Kadınlar4tarafından kullanım için uygun değildir. Tersine, günlük tedavisinde selektif 5-α-redüktaz inhibitörü 1 mg ile serum (DHT) dihidrotestosteron düzeyleri % 70 oranında azaltmak için gösterilmiştir ve saç çapı dereceli artışı ve erkek AGA saç uzama anagen saç saç büyümesini destekler hastalar5,6, saç yoğunluğu önemli artışlar üzerinden. Sözlü selektif 5-α-redüktaz inhibitörü kullanımı en fazla bir yıl tedavi gerekli olabilir ve kullanıcıların Üretilmeyen7ilaçtır sonra hangi kalıcı libido kaybı gelişebilir.
Son zamanlarda, LLLT kullanımı saç büyütme uyarmak için teklif edildi. Afifi vd. 8 LLLT AGA için etkili bir tedavi olup olmadığını belirlemek için varolan araştırma çalışmaları gözden geçirdim. Aktif Otolog trombosit açısından zengin plazma (AA-PRP) topikal uygulama hasat köklerinin implantasyon öncesinde zaten tarafından AGA9, artan saç sergilemek gibi de etkilenen hastaların % 15 onların hayatta kalma oranı artırmak için gösterilmiştir yoğunluğu 3 ay sonrası ameliyat sırasında o zaman1019 oranında artan terminal saç yoğunluğu ile. Bu bulgular tedavi aşağıdaki AGA hasta kalsiyum Aktifleştirilen PRP ile bir yıl11boyunca bir çalışmada teyit edildi.
AA-PRP12 ve A-PRP13 olumlu sonuçlarını bir saç dökülmesi tedavisi ve veri eksikliği klinik enjeksiyon sistemi için göz önüne alındığında, bu çalışmanın birincil amacı mekanik göstermektir ve kontrollü PRP enjeksiyonları protokolü.
18 erkek ve 5 kadın hasta yaşlı 21-70 yaşındaki kim MPHL Stage 2 aşama Norwood-Hamilton sınıflandırma ölçeği tarafından belirlenen 5 için görüntülenen ve Sahne 1 Sahne 2'deki FPHL Ludwig sınıflandırma ölçeği tarafından belirlenen tedavi ile mekanik ve A-PRP enjeksiyonları kontrol. AGA tanılar bir tıbbi geçmiş, trichoscopic analiz, negatif saç çekme testi, laboratuvar testleri ve idrar tahlili ile klinik değerlendirme tarafından yapılmıştır.
AGA aşama Norwood-Hamilton ve Ludwig Skala ile değerlendirilmiştir. Tüm bu çalışmaya dahil katılımcıların bir tıp tarafından değerlendirildi Dermatoloji ve rejeneratif estetik cerrahi ve saç dökülmesi iki plastik cerrah uzman uzman doktor. Yazarlar tüm hastalar için yerelleştirilmiş ve sistemik dışlama ölçütleri olarak kabul. Sistemik kriterleri kan ve/veya trombosit bozuklukları, antikoagülan ve/veya antiaggregation tedavi, sepsis, immünosupresyon, kanser, sözlü selektif 5-α-redüktaz inhibitörü veya antiandrogens kullanımı önceki 12 ay içinde tarafından temsil edildi.
Yerelleştirilmiş dışlama kriterleri diaminopirimidilpiperidin-N-ossido (%2.0 ve % 5.0) veya kortikosteroid önceki 12 ay içinde kullanım için topikal tedaviler tarafından temsil edildi.

<table><tbody><tr><td>C-PunT system</td><td>Biomed Device, Modena, Italy</td><td>www.biomeddevice.it</td><td>a closed system medical device to obtain autologous concentrated platelet-rich plasma from the blood</td></tr><tr><td>Ultim Gun</td><td>Anti-Aging Medical System</td><td>www.aamedicalsystems.fr</td><td>a gun medical device to perform a mechanical and controlled injections of autologous platelet-rich plasma in a selected area of the scalp</td></tr><tr><td>Trichoscan</td><td>Tricolog GmbH, Freiburg, Germany).</td><td>www.tricholog.de</td><td>trihoScan is a digital&lt;br/&gt; software-supported epiluminescence technique for measuring hair count (number of hairs per 0.65 cm2), hair density (number of hairs per cm2), hair diameter, anagen-to-telogen ratio, and vellus&lt;br/&gt; hair-to-terminal hair ratio.</td></tr><tr><td>sodium citrate ACD-A</td><td>S.A.L.F.</td><td>SAAS2205GPO</td><td>anticoagulant for PRP preparation</td></tr><tr><td>&amp;nbsp;30-Gauge needle&amp;nbsp;</td><td>Becton Dickinson&amp;nbsp;</td><td>Z192368</td><td>needle for injections</td></tr><tr><td>10 mL mL Luer-Lock syringe</td><td>Becton Dickinson&amp;nbsp;</td><td>BD309695</td><td>syringe for PRP collection</td></tr></tbody></table>

mechanical and controlled prp injections in patients affected by androgenetic alopecia

Aşama 1 sahne Ludwig tarafından belirlenen 2 sahne 1 aşama Norwood-Hamilton sınıflandırma ölçeği tarafından belirlenen 5 erkek tipi saç dökülmesi (MPHL) ve kadın tipi saç dökülmesi (FPHL) görüntülenen 23 hastalar (18 erkek ve 5 erkek) 21-70 yaş arası sınıflandırma ölçeği, Sigara aktive Otolog trombosit açısından zengin plazma ile (A-PRP) tedavi edildi. Otolog kan (55 mL) sodyum sitrat bir antikoagülan olarak kullanarak hasat. A-PRP (23 mL) kan nakli hizmet protokolüne göre kapalı bir sistem kullanarak tüm servis talepleri için üretildi. Santrifüjü (10 min için 260 x g) ardından A-PRP bir lazer ışık seçici cihazda eklenmiş ve Santrifüjü sonra A-PRP 9 mL denizden çıkarıldı.
Kafa derisi androgenetik alopesi (AGA) tarafından etkilenen hastaların dört alanlara (ön, yan, vertex ve oksipital); bölündü lokal anestezi gerçekleştirilmedi. İnterfollicular A-PRP enjeksiyonları (cm2x 0.2 mL) kontrollü ve mekanik enjeksiyonları tıbbi enjektör silah kullanarak 5 mm derinlikte zamanlanmış tarafından yapıldı. Tedavi oturumları bir 30 günlük aralığı ile gerçekleştirilmiştir. Her bir hasta için üç tedavi oturumlar yapıldı.
PRP kafa derisi saç kaybı tarafından etkilenen androjen ile ilgili alanlarında enjekte ettiler. Plasebo (normal tuzlu çözelti) başka bir şırınga (10 mL) yüklü ve bitişik yan benzer bir şekilde enjekte edilir.

Üç ay sonra tricoscopic analizi tarafından üçüncü A-PRP enjeksiyonları ile temel ölçü birimlerinin ve A-PRP tedavisi ve fizyolojik serum enjeksiyonları olarak alınan denetim alanları arasındaki karşılaştırıldı saç büyüme parametrelerini ölçülen plasebo. Taban çizgisi, vasıl ilk tedavi öncesi yok saç sayısı (122 ± 10) istatistiksel farklılıkları ve saç yoğunluğu (218 ± 17) hedef alan ve kontrollü alan (126 ± 9 temel saç kontrol sayısı alanı), arasında rapor edilmiştir (225 ...

Watch this Scientific Journal Video about Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia at JoVE.com

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Androgenetik alopesi 5 30 gauge iğne ile donatılmış bir tıbbi enjektör silah kullanarak mm derinlikte etkilenen 23 hastaların kafa derisi (cm2x 0,20 mL) interfollicular Otolog trombosit açısından zengin plazma enjeksiyonlar açıklamak için bu kağıt amaçlayan üç oturumları.

Mekanik ve kontrollü PRP enjeksiyonları androgenetik alopesi tarafından etkilenen hastalarda

23 patients (18 male and 5 female) aged 21-70 years who displayed male pattern hair loss (MPHL) in Stage 1 to Stage 5 as determined by the ...

mechanical-controlled-prp-injections-patients-affected-androgenetic

Research

JoVE Journal

Medicine

15.0K Görüntüleme.  University of Rome Tor Vergata. Androgenetik alopesi 5 30 gauge iğne ile donatılmış bir tıbbi enjektör silah kullanarak mm derinlikte etkilenen 23 hastaların kafa derisi (cm2x 0,20 mL) interfollicular Otolog trombosit açısından zengin plazma enjeksiyonlar açıklamak için bu kağıt amaçlayan üç oturumları.

Video: Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain

The central event in the pathogenesis of prion diseases involves a conversion of the host-encoded cellular prion protein PrPC into its pathogenic isoform PrPSc 1. PrPC is detergent-soluble and sensitive to proteinase K (PK)-digestion, whereas PrPSc forms detergent-insoluble aggregates and is partially resistant to PK2-6. The conversion of PrPC to PrPSc is known to involve a conformational transition of &alpha;-helical to &beta;-sheet structures of the protein. However, the in vivo pathway is still poorly understood. A tentative endogenous PrPSc, intermediate PrP* or "silent prion", has yet to be identified in the uninfected brain7.
Using a combination of biophysical and biochemical approaches, we identified insoluble PrPC aggregates (designated iPrPC) from uninfected mammalian brains and cultured neuronal cells8, 9. Here, we describe detailed procedures of these methods, including ultracentrifugation in detergent buffer, sucrose step gradient sedimentation, size exclusion chromatography, iPrP enrichment by gene 5 protein (g5p) that specifically bind to structurally altered PrP forms10, and PK-treatment. The combination of these approaches isolates not only insoluble PrPSc and PrPC aggregates but also soluble PrPC oligomers from the normal human brain. Since the protocols described here have been used to isolate both PrPSc from infected brains and iPrPC from uninfected brains, they provide us with an opportunity to compare differences in physicochemical features, neurotoxicity, and infectivity between the two isoforms. Such a study will greatly improve our understanding of the infectious proteinaceous pathogens. The physiology and pathophysiology of iPrPC are unclear at present. Notably, in a newly-identified human prion disease termed variably protease-sensitive prionopathy, we found a new PrPSc that shares the immunoreactive behavior and fragmentation with iPrPC 11, 12. Moreover, we recently demonstrated that iPrPC is the main species that interacts with amyloid-&beta; protein in Alzheimer disease13. In the same study, these methods were used to isolate Abeta aggregates and oligomers in Alzheimer's disease13, suggesting their application to non-prion protein aggregates involved in other neurodegenerative disorders.

A new species of cellular prion protein (PrPC) has recently been identified in uninfected human brains using the methods described here. These methods can be used to isolate various PrP species, while some of them are also useful in isolating other misfolded protein aggregates from human brains.

Normal İnsan Beyin Çözünür ve çözünmez PrP Oligomerleri İzolasyonu

The central event in the pathogenesis of prion diseases involves a conversion of the host-encoded cellular prion protein PrPC into its pathogenic isoform ...

Tıp

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Implant-associated infection is becoming more and more challenging to the healthcare industry worldwide due to increasing antibiotic resistance, transmission of antibiotic resistant bacteria between animals and humans, and the high cost of treating infections.
In this study, we disclose a new strategy that may be effective in preventing implant-associated infection based on the potential antimicrobial properties of platelet-rich plasma (PRP). Due to its well-studied properties for promoting healing, PRP (a biological product) has been increasingly used for clinical applications including orthopaedic surgeries, periodontal and oral surgeries, maxillofacial surgeries, plastic surgeries, sports medicine, etc.
PRP could be an advanced alternative to conventional antibiotic treatments in preventing implant-associated infections. The use of PRP may be advantageous compared to conventional antibiotic treatments since PRP is less likely to induce antibiotic resistance and PRP's antimicrobial and healing-promoting properties may have a synergistic effect on infection prevention. It is well known that pathogens and human cells are racing for implant surfaces, and PRP's properties of promoting healing could improve human cell attachment thereby reducing the odds for infection. In addition, PRP is inherently biocompatible, and safe and free from the risk of transmissible diseases.
For our study, we have selected several clinical bacterial strains that are commonly found in orthopaedic infections and examined whether PRP has in vitro antimicrobial properties against these bacteria. We have prepared PRP using a twice centrifugation approach which allows the same platelet concentration to be obtained for all samples. We have achieved consistent antimicrobial findings and found that PRP has strong in vitro antimicrobial properties against bacteria like methicillin-sensitive and methicillin-resistant Staphylococcus aureus, Group A Streptococcus, and Neisseria gonorrhoeae. Therefore, the use of PRP may have the potential to prevent infection and to reduce the need for costly post-operative treatment of implant-associated infections.

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Implant-associated infection is a significant clinical complication. This study describes an approach using platelet-rich plasma (PRP) to prevent implant-associated infections, presents the protocol for preparing PRP with constant platelet concentration, and reports the newly identified antimicrobial properties of PRP and related protocols for examining such antimicrobial properties in vitro.

Hazırlama ve: Enfeksiyon Önleme Yeni Bir Yaklaşım olarak PRP<em&gt; In vitro</emPRP&gt; Antimikrobiyal Özellikleri

Implant-associated infection is becoming more and more challenging to the healthcare industry worldwide due to increasing antibiotic resistance, ...

İmmünoloji ve Enfeksiyon

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Autologous platelet concentrates represent promising innovative tools in the field of regenerative medicine and have been extensively used in oral surgery. Unlike platelet rich plasma (PRP) that is a gel or a suspension, Leukocyte-Platelet Rich Fibrin (L-PRF) is a solid 3D fibrin membrane generated chair-side from whole blood containing no anti-coagulant. The membrane has a dense three dimensional fibrin matrix with enriched platelets and abundant growth factors. L-PRF is a popular adjunct in surgeries because of its superior handling characteristics as well as its suturability to the wound bed. The goal of the study is to demonstrate generation as well as provide detailed characterization of relevant properties of L-PRF that underlie its clinical success.

Leucocyte-Platelet Rich Fibrin (L-PRF) represents an FDA cleared preparation of autologous platelet concentrates that possesses unique fibrin architecture, enriched platelets and abundant growth factors. Here, we present a protocol for chair-side generation of L-PRF as well as evaluate its mechanical properties including uniaxial testing and suture retention strength testing.

Lökosit-trombosit Zengin Fibrin, Yeni Bir Biyomateryalinin Karakterizasyonu

Autologous platelet concentrates represent promising innovative tools in the field of regenerative medicine and have been extensively used in oral ...

Biyomühendislik

Preparing Activated Platelet-Rich Plasma for Culturing Human Adipose-Derived Stem Cells

Activated platelet-rich plasma (PRP) prepared from whole blood via centrifugation demonstrated a proliferation-stimulating effect in several kinds of cultured cells, implying a possible use in regenerative medicine. Here, a double-spin method was used to prepare PRP from whole blood. PRP was further activated by autologous thrombin. The platelet count was measured in the activated PRP and the proliferation-stimulating effect in human adipose-derived stem cells (hASCs) was examined. The resulting platelet count was 11.5-times higher in PRP than in whole blood plasma. The proliferation of hASCs was markedly enhanced by incubation with 1% PRP. The described method can be used to reproducibly prepare PRP with a high concentration of platelets. PRP prepared by this method markedly promotes proliferation of hASCs.

In this report, we describe a double-spin method for preparing activated platelet-rich plasma (PRP). Using autologous thrombin, human adipose-derived stem cells (hASCs) were cultured. Activated PRP was shown to promote proliferation of hASCs.

Activated platelet-rich plasma (PRP) prepared from whole blood via centrifugation demonstrated a proliferation-stimulating effect in several kinds of ...

Gelişim Biyolojisi

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

There is currently great clinical interest in the use of autologous fibroblasts for skin repair. In most cases, culture of skin cells in vitro is required. However, cell culture using xenogenic or allogenic culture media has some disadvantages (i.e., risk of infectious agent transmission or slow cell expansion). Here, an autologous culture system is developed for the expansion of human skin fibroblast cells in vitro using a patient&#8217;s own platelet-rich plasma (PRP). Human dermal fibroblasts are isolated from the patient while undergoing abdominoplasty. Cultures are followed for up to 7 days using a medium supplemented with either fetal bovine serum (FBS) or PRP. Blood cell content in PRP preparations, proliferation, and fibroblast differentiation are assessed. This protocol describes the method for obtaining a standardized, non-activated preparation of PRP using a dedicated medical device. The preparation requires only a medical device (CuteCell-PRP) and centrifuge. This device is suitable under sufficient medical practice conditions and is a one-step, apyrogenic, and sterile closed system that requires a single, soft spin centrifugation of 1,500 x g for 5 min. After centrifugation, the blood components are separated, and the platelet-rich plasma is easily collected. This device allows a quick, consistent, and standardized preparation of PRP that can be used as a cell culture supplement for in vitro expansion of human cells. The PRP obtained here contains a 1.5-fold platelet concentration compared to whole blood together, with a preferential removal of red and white blood cells. It is shown that PRP presents a boosting effect in cell proliferation compared to FBS (7.7x) and that fibroblasts are activated upon PRP treatment.

This protocol presents a device that produces PRP to boost the in vitro expansion of cells in a 100% autologous fibroblast culture system.

In Vitro İnsan Fibroblast Genişlemesini Artırmak için Otolog Trombosit Bakımından Zengin Plazma Üretimi

There is currently great clinical interest in the use of autologous fibroblasts for skin repair. In most cases, culture of skin cells in vitro is ...

Effects of Allogeneic Platelet-Rich Plasma (PRP) on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

This article describes the experimental procedures used to observe if PRP can positively affect tendon healing. There are 4 main steps to follow: induce a lesion in the Achilles tendon; prepare PRP and inject it (or the saline solution); remove the tendon; and perform biomechanical, molecular, and histological evaluations. At each step, all the procedures and methods are described in detail, so they can be reproduced easily.
Achilles tendons have been surgically sectioned (removal of a 5-mm long section). Afterwards, PRP or saline solution was injected to study whether PRP has a positive effect on the healing of the tendon. Three groups of 40 animals (a total of 120 rats were used in this study) were subdivided into 2 subgroups: PRP injection group and a saline injection control group. Rats were sacrificed at increasing time points (Group A: 5 days; Group B: 15 days; Group C: 30 days) and tendons were removed. 90 tendons underwent biomechanical testing before performing transcriptomic analysis and the 30 remaining tendons were submitted to histological analysis.

Effects of Allogeneic Platelet-Rich Plasma PRP on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

This protocol describes the evaluation process of healing tendons in rats that have been injected with allogeneic platelet rich plasma (PRP) or saline solution after removing part of the Achilles tendon. The progress of tendon healing is evaluated at several time points using different types of analyses.

Allojeneik trombosit açısından zengin plazma (PRP) kesitli Aşil tendon sıçan iyileşme süreci üzerine etkileri: metodolojik bir açıklama

This article describes the experimental procedures used to observe if PRP can positively affect tendon healing. There are 4 main steps to follow: induce a ...

Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis

Knee osteoarthritis (KOA) is one of the most frequently encountered diseases in the orthopedic department. Existing non-surgical treatments have a limited effect on the repair of cartilage and on bone regeneration. Platelet-rich plasma (PRP) is an autologous bioactive substance that can repair cartilage injury and accelerate bone regeneration effectively. However, reporting of PRP preparation protocols in clinical studies is highly inconsistent, with the majority of studies providing insufficient information to allow the protocol to be reproduced. We describe a repeatable method of preparing PRP visually, the treatment of KOA using PRP intra-articular injection, and methods of evaluating the outcome. PRP was prepared using manual double centrifugation. The PRP layer was extracted from peripheral blood and used for knee joint cavity injection. Evaluations included assessments of blood platelet concentrations and clinical outcomes. Preparation of PRP by manual centrifugation requires less apparatus and is less costly than plasma filtration or centrifugation using equipment. The centrifugation time of our double centrifugation method was 6 and 5 minutes for the respective centrifugations at forces of 800 and 1400 x g, respectively, to allow for the consistent preparation of standardized PRP. However, a manual method is susceptible to operator error, and PRP batch preparation is not available. Intra-articular injection of PRP proved to be an effective treatment for knee osteoarthritis. The entire treatment procedure took less than 30 minutes, the blood platelet concentration of PRP could be standardized, and treatment was proven to be effective when evaluated by follow-up.

Knee osteoarthritis is frequently seen in the orthopedic department. We introduce in detail the entire knee osteoarthritis treatment process with platelet-rich plasma injection, including preparation, procedures, and evaluation.

Hazırlık, yordamlar ve trombosit açısından zengin plazma enjeksiyon diz osteoartriti tedavisinde değerlendirilmesi

Knee osteoarthritis (KOA) is one of the most frequently encountered diseases in the orthopedic department. Existing non-surgical treatments have a limited ...

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Alopecia is a common form of hair loss which can occur in many different conditions, including male-pattern hair loss, polycystic ovarian syndrome, and alopecia areata. Alopecia can also occur as a side effect of chemotherapy in cancer patients. In this study, our goal was to develop a consistent and reliable method to quantify hair loss in mice, which will allow investigators to accurately assess and compare new therapeutic approaches for these various forms of alopecia. The method utilizes a standard gel imager to obtain and process images of mice, measuring the light absorption, which occurs in rough proportion to the amount of black (or gray) hair on the mouse. Data that has been quantified in this fashion can then be analyzed using standard statistical techniques (i.e., ANOVA, T-test). This methodology was tested in mouse models of chemotherapy-induced alopecia, alopecia areata and alopecia from waxing. In this report, the detailed protocol is presented for performing these measurements, including validation data from C57BL/6 and C3H/HeJ strains of mice. This new technique offers a number of advantages, including relative simplicity of application, reliance on equipment which is readily available in most research laboratories, and applying an objective, quantitative assessment which is more robust than subjective evaluations. Improvements in quantification of hair growth in mice will improve study of alopecia models and facilitate evaluation of promising new therapies in preclinical studies.

Alopecia is a common form of hair loss which can occur in many different conditions, including as a side-effect of chemotherapy. We have developed a method to quantify hair loss in mice, utilizing a standard gel imager to perform a grayscale analysis, to facilitate study of promising new alopecia therapies.

Gri tonlama Analizi İle Farelerde Saç Dökülmesi Kantitatif Analiz Yeni Bir Teknik

Alopecia is a common form of hair loss which can occur in many different conditions, including male-pattern hair loss, polycystic ovarian syndrome, and ...

Biyoloji

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Various ocular surface diseases are treated with blood-derived eye drops. Their use has been introduced in clinical practice because of their metabolite and growth factor content, which promotes eye surface regeneration. Blood-based eye drops can be prepared from different sources (i.e., whole blood or platelet apheresis donation), as well as with different protocols (e.g., different dilutions and freeze/thaw cycles). This variability hampers the standardization of clinical protocols and, consequently, the evaluation of their clinical efficacy. Detailing and sharing the methodological procedures may contribute to defining common guidelines. Over the last years, allogenic products have been diffusing as an alternative to the autologous treatments since they guarantee higher efficacy standards; among them, the platelet-rich plasma lysate (PRP-L) eye drops are prepared with simple manufacturing procedures. In the transfusion medicine unit at AUSL-IRCCS di Reggio Emilia, Italy, PRP-L is obtained from platelet-apheresis donation. This product is initially diluted to 0.3 x 109 platelets/mL (starting from an average concentration of 1 x 109 platelets/mL) in 0.9% NaCl. Diluted platelets are frozen/thawed and, subsequently, centrifuged to eliminate debris. The final volume is split into 1.45 mL aliquots and stored at &#8722;80 &#176;C. Before being dispensed to patients, eye drops are tested for sterility. Patients may store platelet lysates at &#8722;15 &#176;C for up to 1 month. The growth factor composition is also assessed from randomly selected aliquots, and the mean values are reported here.

Platelet lysates represent an emerging tool for the treatment of ocular surface diseases. Here, we propose a method for the preparation, dispensation, storage, and characterization of platelet lysate collected from platelet donors.

Göz Yüzeyi Hastalıklarının Tedavisinde Trombositten Zengin Plazma Lizat

Various ocular surface diseases are treated with blood-derived eye drops. Their use has been introduced in clinical practice because of their metabolite ...

A Platelet-Rich Plasma Injection into the Sectioned Achilles Tendon of a Rat

Source: Greimers, L., et al. <a href="https://app.jove.com/v/55759">Effects of Allogeneic Platelet-Rich Plasma (PRP) on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description.</a> J. Vis. Exp. (2018).
This video demonstrates a technique for injecting platelet-rich plasma (PRP) into the sectioned Achilles tendon of rats. A small segment is excised from the Achilles tendon of a recipient rat, the site is sutured, and the rat is allowed to recover. Concurrently, whole blood is collected from a donor rat and centrifuged to obtain PRP, which is then activated and injected into the sutured site of the recipient rat to induce tendon repair.

Bir Sıçanın Kesitli Aşil Tendonu İçine Trombositten Zengin Plazma Enjeksiyonu

All procedures involving animal models have been reviewed by the local institutional animal care committee and the JoVE veterinary review board.
1. Animal ...

Mekanik ve kontrollü PRP enjeksiyonları androgenetik alopesi tarafından etkilenen hastalarda

Özet

Daha Fazla Video Keşfet

PLAYLIST